Objectives: Given the high frequency of acute pulmonary exacerbations due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF), piperacillin/tazobactam is commonly used in empirical regimens. While extended-infusion piperacillin/tazobactam has been employed as one strategy to optimize this agent's pharmacodynamics, this approach has not been well characterized in patients with CF. The objectives of this study were to characterize the pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with CF and derive optimized piperacillin/tazobactam dosing recommendations.
Introduction
Acute pulmonary exacerbations secondary to chronic bacterial colonization of the respiratory tract are estimated to cause 90% of deaths in patients with cystic fibrosis (CF). 1 Although there are a wide range of causative pathogens, Pseudomonas aeruginosa accounts for this chronic bacterial colonization in nearly 80% of adults with CF. 2 Given that eradication of P. aeruginosa is often not possible, antibiotic dosing should be optimized in an effort to reduce the respiratory bacterial burden and improve clinical symptomatology. 3 A common empirical antipseudomonal antimicrobial regimen used to treat these patients consists of piperacillin/tazobactam and tobramycin. Over time, strategies have been implemented to optimize the dosage of tobramycin in this population, and guidelines now recommend higher daily doses and therapeutic drug monitoring. 3, 4 In contrast, piperacillin/tazobactam is given at the same dose in patients with or without CF. This is concerning given that the probability of target attainment (PTA) for piperacillin/ tazobactam has been shown to be suboptimal (,90%) using standard FDA-approved dosing in patients without CF. 5 -8 Extending the duration of infusion can increase the PTA, but there are limited data on the PTA of extended-infusion piperacillin/tazobactam in patients with CF. 6,9 -15 The objectives of this study were to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of extended-infusion piperacillin/tazobactam in adult patients with CF and derive optimized dosing recommendations.
Methods
The study protocol was approved by the Institutional Review Board of Albany Medical Center Hospital (AMCH) (Albany, NY, USA), and written informed consent was obtained from each patient. Adult patients (≥18 years of age) with CF who were receiving piperacillin/tazobactam for # The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2014; 69: 176 -179 doi:10.1093/jac/dkt300 Advance Access publication 18 July 2013 acute pulmonary exacerbations requiring hospitalization were eligible for this study. Patients were excluded if any of the following criteria were met: (i) unable to tolerate venipuncture and multiple blood collections; (ii) female subject who was known to be pregnant; (iii) admitted to the intensive care unit; (iv) estimated creatinine clearance ,50 mL/min; and (v) any known hypersensitivity to piperacillin/tazobactam.
As standard hospital protocol, patients were administered 3 g of piperacillin in combination with 0.375 g of tazobactam intravenously (iv) every 8 h for 4 h. All patients were also receiving tobramycin as part of their empirical regimen. The patient's demographic information, past medical history, history of present illness, clinical laboratory data and dosing information were reviewed and documented.
Six blood samples were collected from patients at the following timepoints: just prior to the piperacillin/tazobactam dose being studied (0 h), mid-infusion (2 h), post-infusion (4 h) and at 5, 6.5 and 8 h from the start of infusion. Serum samples were assayed as a batch by the Center for AntiInfective Research and Development at Hartford Hospital (Hartford, CT, USA) for piperacillin concentrations by use of a validated HPLC method described previously. 8 All data were analysed in a population PK model using BigNPAG. 9 Three two-compartment structural models were evaluated as previously described: 5, 7 (i) elimination as a first-order process; (ii) Michaelis-Menten (MM) process alone; and (iii) an MM process with parallel first-order elimination. Discrimination between the models was accomplished by the rule of parsimony based on Akaike's information criterion (AIC). Upon attaining convergence, maximal a posteriori probability (MAP) Bayesian estimates for each patient were obtained using the 'population of one' utility in BigNPAG. 9 After the Bayesian step, goodness of fit and predictive performance were assessed. 5 Embedded with the final PK model, a series of 5000-subject Monte Carlo simulations (MCSs) were performed using ADAPT 5. 10 Protein binding for patients with and without CF is similar for most drugs, including b-lactams, 11 and so a fixed protein binding of 30% was assumed to reflect unbound concentrations. 5 Simulations were performed for piperacillin using a standard infusion (30 min) of 3 and 4 g every 6 h and 4 g every 8 h, extended infusion (4 h) of 3 g every 8 h, extended infusion (3 h) of 3 and 4 g every 6 h and continuous infusion (24 h) of 12 and 16 g daily. Simulations were based on a 24 h dosing regimen. For each regimen examined, the fraction of simulated subjects who achieved free concentrations above the MIC for at least 50% of the dosing interval (50% T .MIC ) was calculated for piperacillin MICs ranging from 0.25 to 128 mg/L. The population simulation without process noise option was utilized and log-normal distributions of PK parameters were selected for all simulations.
Results
Nine adult patients were enrolled in the study a mean (SD) of 4.1 (2.5) days into admission. The mean (SD) age was 33.0 (12.6) years, and the majority of patients were female (88.9%) and Caucasian (100%). Average (SD) weight and body mass index were 53.6 (6.5) kg and 20.0 (2.7) kg/m 2 , respectively. Mean (SD) population parameter estimates identified by BigNPAG for the linear, MM and parallel first-order/MM models are provided in Table 1 . Goodness of fit and predictive performance for each structural model are also displayed in Table 1 . The MM model was selected as the final model based on the AIC and goodness-of-fit statistics.
The fractions of simulated subjects who achieved 50% T .MIC against a range of MICs for various dosing regimens are displayed in Figure 1(a and b) . For standard 30 min infusion doses, the PTA was .90% for MICs ≤2 mg/L. Against MICs of 4 mg/L, 4 g iv every 6 h for 30 min and all dosing regimens consisting of a prolonged or continuous infusion had a PTA .90%. Acceptable PTA against MICs of 8 mg/Lwas only seen with prolonged or continuous infusion dosing regimens, with the exception of 3 g iv for 4 h every 8 h (PTA of 87%). Against MICs of 16 mg/L, prolonged or continuous infusions of 12 g/day were estimated to provide 70% PTA, but a dose of 4 g iv every 6 h as a 3 h infusion and the same total daily 
Discussion
This study sought to characterize the PK and PD of extended-infusion piperacillin/tazobactam in adult patients with CF hospitalized for acute pulmonary exacerbations. Overall, we found the serum PK of piperacillin to be best explained by an MM model. Our results match up well to previous PK analyses with methodology similar to ours. In patients with CF, Vinks et al. 12 also found that an MM model best fitted the data. The population estimates for V max and the MM constant were 2284 mg/h and 92.3 mg/L, respectively, making their calculated intrinsic clearance (CL; V max /K m ) 24.7 L/h. 12 These estimates are consistent with our observed V max , K m and calculated intrinsic CL of 19.4 L/h. Similarly, Felton et al. 7 also reported similar population estimates for V max , K m and calculated intrinsic CL in patients without CF (1634.7 mg/h, 78.6 mg/L and 20.8 L/h, respectively). In contrast, Bulitta et al. 13 demonstrated that linear elimination accounted for most of the CL of piperacillin, but this may be explained by differences in study drug administration and study population.
Despite the differences in final model selection and parameter estimates across studies, the clinical consequences of the high intrinsic CL estimates for piperacillin/tazobactam in adult CF patients were highly apparent in our MCS analyses. Suboptimal exposure profiles were associated with all conventional intermittent infusions of piperacillin in adult patients with CFagainst susceptible pathogens with MICs .4 mg/L. In contrast, prolonged or continuous infusion regimens achieved nearly optimal PTA against MICs up to 16 mg/L. Although the same daily doses given as a prolonged infusion are predicted to achieve slightly better PTA than a continuous infusion, the differences were minimal. Since continuous infusion may be a preferred method of administration by patients with CF, the choice between the two regimens should be discussed individually with each patient.
While our findings demonstrate that prolonging the infusion of piperacillin/tazobactam will enhance PD exposures against pathogens with higher MICs, some analyses suggest that MIC is not predictive of outcome in patients with CF. 14, 15 Furthermore, a number of studies have demonstrated that prolonged infusion reduces mortality in patients without CF, 16 but outcomes data in patients with CF are very limited. Further data are needed to better understand the clinical implications of MIC testing and prolonged infusion b-lactam therapy among patients with CF. In addition, since concentrations at the site of infection are critical for obtaining a good outcome, further analyses are needed to evaluate the penetration and PD of piperacillin/tazobactam in the lungs of patients with CF. Finally, although our MCS findings provide a good estimate of piperacillin/tazobactam exposures likely to be observed in practice among patients with CF, our analysis included a limited number of PK samples and patients. It is important that our results be validated in a larger patient population in the clinical setting.
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